← Leaderboards
Shahriar Koochekpour
Lsu Health Sciences Center
$4,133,739
Attributed
$4,133,739
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $912.8K · FY2006–15$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$4,133,739 · 11
By mechanism
R21$1,767,184 · 5
R01$1,512,198 · 1
P20$854,357 · 5
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroCellsMalignant Neoplasm Of ProstateTissuesCell LineMigrationProstateCancer CellStagingMolecularGrowthBenignBaseBiologicalPc3 Cell LineAndrogensNeoplasm MetastasisGleason Grade For Prostate CancerAfrican AmericanOverexpressionIncidenceMalignant - DescriptorMortality Vital StatisticsCancer Patient
Grant awards (21)
Therapeutic Efficacy of Riluzole in Prostate Cancer$221,589
R21 · FY2015 · CA · contact PI
Metabotropic Glutamate Receptor 1 in African American Prostate Cancer$184,658
R21 · FY2015 · CA · contact PI
Metabotropic Glutamate Receptor 1 in African American Prostate Cancer$221,589
R21 · FY2014 · CA · contact PI
Therapeutic Efficacy of Riluzole in Prostate Cancer$184,658
R21 · FY2014 · CA · contact PI
Prosaposin: A Novel Biomarker of Prostate Cancer Progression in African Americans$391,670
R01 · FY2013 · MD · contact PI
Prosaposin: A Novel Biomarker of Prostate Cancer Progression in African Americans$414,078
R01 · FY2012 · MD · contact PI
PROSAPOSIN, A NOVEL INFLAMMATORY RESPONSE FACTOR FOR PROSTATE CANCER PROGRESSION$200,369
P20 · FY2011 · RR · contact PI
Prosaposin: A Novel Biomarker of Prostate Cancer Progression in African Americans$182,713
R01 · FY2011 · MD · contact PI
Prosaposin: A Novel Biomarker of Prostate Cancer Progression in African Americans$168,737
R01 · FY2011 · MD · contact PI
Prognostic value of AR mutation in primary African American prostate cancer$153,684
R21 · FY2011 · CA · contact PI
Significance of an novel germline AR mutation in black men with prostate cancer$115,161
R21 · FY2011 · CA · contact PI
Significance of an novel germline AR mutation in black men with prostate cancer$34,632
R21 · FY2011 · CA · contact PI
Prosaposin: A Novel Biomarker of Prostate Cancer Progression in African Americans$355,000
R01 · FY2010 · MD · contact PI
Prognostic value of AR mutation in primary African American prostate cancer$199,777
R21 · FY2010 · CA · contact PI
Significance of an novel germline AR mutation in black men with prostate cancer$185,310
R21 · FY2010 · CA · contact PI
PROSAPOSIN, A PROMOTER OF PROSTATE CARCINOGENESIS$172,755
P20 · FY2010 · RR · contact PI
PROSAPOSIN, A PROMOTER OF PROSTATE CARCINOGENESIS$198,775
P20 · FY2009 · RR · contact PI
PROSAPOSIN, A PROMOTER OF PROSTATE CARCINOGENESIS$139,462
P20 · FY2008 · RR · contact PI
LSUHSC COBRE: PROJ 1: PRESPOSIN, A PROMOTER OF PROSTATE CARCINOGENESIS$142,996
P20 · FY2007 · RR · contact PI
Prosaposin, a novel tumor marker for prostate cancer$130,988
R21 · FY2007 · CA · contact PI
Prosaposin, a novel tumor marker for prostate cancer$135,138
R21 · FY2006 · CA · contact PI